Sugi Predict

Sugi Predict / Targets / PTPN1

PTPN1

Tyrosine-protein phosphatase non-receptor type 1 · P18031 · PTPN1 on Sugi Atlas →

535,546 patent compounds predicted against PTPN1, 317,837 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Genipin Genipin (SCHEMBL34249) 0.70 9/20
SCHEMBL7621 SCHEMBL7621 1.00 7/20
Chlorogenic Acid Chlorogenic Acid (SCHEMBL19466) 1.00 6/20
SCHEMBL23003 SCHEMBL23003 0.58 5/20
Tiron Tiron (SCHEMBL22220) 0.57 5/20
SCHEMBL31393 SCHEMBL31393 0.53 5/20
SCHEMBL34887 SCHEMBL34887 0.52 5/20
SCHEMBL35382 SCHEMBL35382 0.52 5/20
SCHEMBL21621 SCHEMBL21621 0.48 5/20
2-Undecylenic Acid 2-Undecylenic Acid (SCHEMBL17828) 0.68 4/20
SCHEMBL20072 SCHEMBL20072 0.68 4/20
Phaseolin Phaseolin (SCHEMBL33735) 0.67 4/20
Phaseolin Phaseolin (SCHEMBL33736) 0.67 4/20
Glycyrrhizin Glycyrrhizin (SCHEMBL17684) 0.63 4/20
SCHEMBL17051 SCHEMBL17051 0.55 4/20
SCHEMBL26502 SCHEMBL26502 0.50 4/20
Phytonadione Phytonadione (SCHEMBL3882) 0.48 4/20
SCHEMBL21486 SCHEMBL21486 0.44 4/20
Stearic Acid Stearic Acid (SCHEMBL659) 1.00 3/20
Oleic Acid Oleic Acid (SCHEMBL1138) 1.00 3/20

Clinical trials — most relevant to PTPN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Immunoregulatory Therapy for 2019-nCoV PHASE2UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer PHASE2RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma PHASE2UNKNOWN
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer PHASE2UNKNOWN
TORI 104 Pre-Surgical Dasatinib PHASE2WITHDRAWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors PHASE1RECRUITING
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Resistance to Immunotherapy in Gastric Cancer nanUNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis nanCOMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN1 binder may also engage these)

ProteinNameSimilarity
P20417 — 0.996 P20417 →
O13016 — 0.988 O13016 →
P35821 — 0.987 P35821 →
O88508 — 0.936 O88508 →
Q4W5Z4 — 0.935 Q4W5Z4 →
Q1LZ53 — 0.935 Q1LZ53 →
Q4V8K3 — 0.932 Q4V8K3 →
NAA10 N-alpha-acetyltransferase 10 0.931 landscape →
Q2KI14 — 0.931 Q2KI14 →
DNMT3A DNA (cytosine-5)-methyltransferase 3A 0.930 landscape →
Q9BSU3 — 0.930 Q9BSU3 →
Q9QY36 — 0.929 Q9QY36 →
Q3UX61 — 0.929 Q3UX61 →
Q01134 — 0.926 Q01134 →
CHKA Choline kinase alpha 0.923 landscape →
G3V6U9 — 0.922 G3V6U9 →
KCNAB1 Voltage-gated potassium channel subunit beta-1 0.922 landscape →
Q3V1L4 — 0.921 Q3V1L4 →
Q7RTP6 — 0.920 Q7RTP6 →
B5FW36 — 0.920 B5FW36 →
A9X1D0 — 0.920 A9X1D0 →
O54804 — 0.919 O54804 →
G3MWR8 — 0.919 G3MWR8 →
B0VX69 — 0.917 B0VX69 →
A0A2R8QFQ6 — 0.917 A0A2R8QFQ6 →
Q95KH6 — 0.917 Q95KH6 →
GLS Glutaminase kidney isoform, mitochondrial 0.917 landscape →
Q9D300 — 0.917 Q9D300 →
Q62356 — 0.917 Q62356 →
Q91WC0 — 0.916 Q91WC0 →